Acrivon Therapeutics (ACRV) announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment, CLIA, certified laboratory, located on premises in Watertown. This facility has received CLIA certification from the state of Massachusetts and is expected to become fully operational during the first half of 2026. The CLIA certification signifies that the lab operates in accordance with CLIA regulations, which are federal standards applicable to all U.S. facilities testing human specimens for health assessment, diagnosis, prevention, or treatment of diseases and ensures high standards for accuracy and reliability in laboratory testing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- 3 Best Stocks to Buy Today, 1/22/2026, According to Top Analysts
- Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler
- Balancing Early Promise and Significant Uncertainty: Maintaining a Hold on Acrivon Therapeutics Amid Limited Data and Long-Dated Clinical Risk
- Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!